Biosimilars

Adalimumab-atto will be used to treat several inflammatory diseases, including rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

Real-world evidence indicates that patients with psoriasis can safely and effectively undergo (non-medical) switching to a biosimilar.

Shifts towards on-patient and higher-cost therapies have been observed in TNF-alpha inhibitor biosimilar availability. Therefore, the importance of investing in biosimilars is encouraged.

The safety and efficacy of 4 adalimumab biosimilars was compared in a real-life setting in adult patients with IBD switching from the originator for a non-medical reason.

A phase 4, post-marketing surveillance study in Korea provides insight into the safety and efficacy of SB2, an infliximab biosimilar, across a wide range of immune-mediated inflammatory diseases, including rheumatoid arthritis, ulcerative colitis, and ankylosing spondylitis.

New research indicates that rheumatoid arthritis patients switching to biosimilars to adalimumab may see improved outcomes by sticking with their original treatment.

The etanercept biosimilar, YLB113 (Nepexto), maintained a favorable efficacy, safety, and immunogenicity profile through week 96.

Disease-dependent factors, such as a history of adverse reactions to bio-originators and disease activity, influenced patients' acceptance of switching from a biologic to a biosimilar.

Results of the study, which focused on patient-reported outcomes in addition to clinical measurements, mirror findings from other large-scale studies evaluating the safety and efficacy of biosimilars in patients with rheumatoid arthritis.

Although patients with inflammatory conditions reported positive attitudes towards biologic treatment, they were far less familiar with biosimilars, indicating the need for clinicians to provide patient education more effectively.

At the 6-month mark, there were no significant differences between the treatment groups regarding composite score-defined remission.